Cidara, Janssen To Tackle Flu With Antiviral Conjugates
Cidara partners its antiviral conjugate platform for seasonal and pandemic influenza with Janssen, which also gets option rights to an AVC candidate for respiratory syncytial virus.
You may also be interested in...
Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.
BIO 2020 Notebook: Fauci On Price Controls; Biotech's Financing Advantage; Progress Towards Universal Flu Vaccine
News and views from day two of BIO Digital include Jim Greenwood on the prospects for drug development legislation.
Mundipharma is to provide financial support and development expertise for Cidara’s Phase III clinical studies of its once-weekly echinocandin antifungal for serious infections, in return for ex-US and ex-Japanese marketing rights.